Marimekko Corporation, Press release, 30 November 2016 at 8.30 a.m. Throughout 2017, the 100th anniversary of Finland’s independence, Marimekko will encourage participation in and create opportunities for innovation. In collaboration with Slush, Europe’s leading event for technology and start-ups, and Junction, the largest hackathon in Europe, produced by Aalto Entrepreneurship Society (Aaltoes), we will organise a competition entitled Marimekko Designathon for the new generation of creators, where we will look for new innovative ideas and solutions challenging the conventions of traditional textile and clothing industry. The Marimekko Designathon competition combining design and technology will be held as a hackathon at Marimekko’s headquarters in Helsinki in September 2017 and it will be one of the events of Helsinki Design Week. A jury composed of international experts and the competition organisers will select the best ideas, and the winners will have the opportunity to present their ideas at Slush 2017. “We will build a successful future for Finland by doing things together and crossing boundaries open-mindedly. With the Marimekko Designathon competition, we want to invite younger generation creators to challenge the traditional conventions of our industry and develop fresh and unprecedented ideas. The project brings together trailblazing Finnish design and technology in a new way, and we can’t wait to see what innovative solutions, new beginnings, might come out of the collaboration,” says Tiina Alahuhta-Kasko, President and CEO of Marimekko. “Unique design and user experience are the cornerstones of the success of many thriving start-ups. Collaboration with Marimekko will open the door for the Slush start-up community to a completely new area of expertise, which in the long term will hopefully have a significant positive impact on the design know-how of local start-ups,” notes Slush CEO Marianne Vikkula. “At Junction, we are excited about breaking down barriers between design and technology through our collaboration with the timeless design house Marimekko. The experimental culture of a hackathon such as Junction presents companies with a new and different way to start developing their own business. To the younger generation of creators, the collaboration between Junction and Marimekko is an encouraging example – it will inspire future top professionals to develop their skills broadly and challenge established industries with new innovations and ideas,” says Ville Leppälä, Head of Junction. Print pattern to symbolise collaboration Maija Louekari, a younger generation print designer, has created a pattern entitled Hyvä myrsky (good storm) to symbolise the collaboration between Marimekko, Slush and Junction. The pattern was inspired by a thought of a brainstorm where bold ideas and people meet and new beginnings are born. In the pattern, multi-interpretative storm clouds and flashes of lightning form a good storm which freshens the surrounding world and so enables something new to emerge. Further details about Marimekko’s projects and events related to the centenary are available, inter alia, at www.marimekko.com . Photo of the Hyvä myrsky pattern: http://mediabank.marimekko.fi/l/FnLwKk2jntrB Additional information: Asta Halme, Marimekko Communications Tel. +358 9 7587 233 asta.halme@marimekko.com DISTRIBUTION: Key media Marimekko is a Finnish design company renowned for its original prints and colours. The company’s product portfolio includes high-quality clothing, bags and accessories as well as home décor items ranging from textiles to tableware. When Marimekko was founded in 1951, its unparalleled printed fabrics gave it a strong and unique identity. Marimekko products are sold in about 40 countries. In 2015, brand sales of the products worldwide amounted to EUR 186 million and the company's net sales were approximately EUR 96 million. More than 150 Marimekko stores serve customers around the globe. The key markets are Northern Europe, North America and the Asia-Pacific region. The Group employs about 400 people. The company’s share is quoted on Nasdaq Helsinki Ltd. www.marimekko.com.
MARIMEKKO TEAMS UP WITH SLUSH AND JUNCTION TO FIND BOLD
Top 10 Most Recent News Articles
Ensign Lawsuit Brews: Investor Stakes High by Dec. 7
Ensign's Alleged Missteps Uncovered Man, grabbing headlines in the finance world often feels like catching a whirlwind, and yet, here we are with Ensign Group's latest debacle. This isn't some run-of-the-mill story we're sifting through. It's a class action lawsuit with teeth, aiming to rope in investors who played ball during a hefty stretch running from February 10,...
Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle
Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...
Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety
Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...
Continue Reading
Hims & Hers Faces Securities Lawsuit Amid Stock Dive
Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...
Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists
Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...
Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move
Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...
Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?
A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...
Continue Reading
Duolingo Faces Class Action: Deadline Looms for Plaintiffs
Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...
Continue Reading
York Space Systems Class Action: Deadline Approaches
Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...
Continue ReadingTop 5 Most Recently Viewed Articles
MAAS Embraces Healthcare with Strategic Carve Group Acquisition
MAAS Expands into Healthcare and Wellness Maase Inc. (NASDAQ: MAAS) recently announced a significant expansion into the healthcare and wellness sector following its acquisition of Carve Group Ltd. This strategic move signifies MAAS's commitment to innovate within the traditional wellness product landscape by integrating advanced biotechnology. The acquisition is more than...
Continue Reading
Metavesco Welcomes ADHC's Strategic Purchase of OTCfi Tokens
Metavesco Celebrates Collaboration with ADHC In a significant development, Metavesco, Inc. (NASDAQ: MVCO) recently expressed excitement over American Diversified Holdings Corporation (NASDAQ: ADHC) announcing their Digital Asset Treasury (DAT) purchase of OTCfi tokens. This partnership is seen as a positive move towards enhancing the visibility and growth of the...
Continue Reading
Understanding Short Interest Trends in Discover Financial
Understanding Short Interest Trends in Discover Financial Discover Financial's stock ticker, DFS, has recently experienced an increase in its short interest, rising to 10.94% since the last report. The total number of shares sold short now stands at 3.11 million, equating to 1.42% of the available shares for trading. If we consider the current trading volume, it would...
Continue Reading
Immunic Reaches Key Milestone in Multiple Sclerosis Trials
Immunic Completes Enrollment in Phase 3 Trials Immunic, Inc. (NASDAQ: IMUX), a pioneering biotechnology firm, recently reached a significant milestone by completing enrollment for its Phase 3 ENSURE trials, which focus on its lead drug, vidofludimus calcium. These trials target patients living with relapsing multiple sclerosis (RMS) and aim to evaluate the drug's...
Continue Reading
Ergonomic Apparel Revolution: Elevating Back Health in Daily Life
Rising Trend of Ergonomic Posture Wear The growing trend of ergonomic apparel highlights the importance of posture-related health concerns. As people spend more time seated and engaged with screens, discomfort is becoming increasingly common. A recent review has brought attention to this phenomenon, shedding light on how ergonomic clothing can play a pivotal role in...
Continue Reading